Dynasil Corp Of America · OTC:DYSL
Dynasil Corp Of America — Corporate Update (November 2016)
17 slides from Dynasil Corp Of America's corporate update, Nov 18, 2016
Slide 1: Dynasil Corporation of America Xcede Conference Call
Dynasil Corporation of America Xcede Conference Call November 21, 2016
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements The statements made in this presentation which are not statements of historical fact are forward looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Forward - looking statements i
Slide 3: Agenda
Agenda • What is this Product? • Why is it Important? • How Much is the Financing? • When? – Timeline to Launch 3
Slide 4: What is this Product?
ws wr », > What is this Product?
Slide 5: Xcede Hemostatic Patch
Xcede Hemostatic Patch • Proprietary combination of a thin layer of Cook Biotech Inc.’s extracellular matrix technology combined with Xcede adhesive technology • Fully bio - resorbable • Stops bleeding during surgical procedures in 60 seconds • No prep time & easy to use: − Open package and apply di
Slide 6: Why is it Important?
Product Efficacy Anticipated Pharmacoeconomics Market Opportunity Xcede Patch Why is it Important?
Slide 7: Impressive Pre-Clinical Performance
Impressive Pre - Clinical Performance 7 Rapid time to hemostasis (stops bleeding) in preclinical studies have impressed surgeons: “ The Xcede Patch stops bleeding within 60 seconds in preclinical animal studies – an impressive time to hemostasis. It could be a significant new technology in the topic
Slide 8: Beneficial for Patients and Hospital Payors
Beneficial for Patients and Hospital Payors 1. Achieving Hemostasis in 60 seconds may prevent significant blood loss and prevent related complications: – Reduced need for transfusions and blood products use – Reduced lack of blood to major organs (i.e., ischemia) – Unbalanced concentrations of coagu
Slide 9: Significant Market Opportunities
Significant Market Opportunities 9 $537 million $87 million $1.09 billion $465 million Untapped Severe Bleeding Market $42 million – Hospital $32 million – EMS/Law Enforcement $7.5 million – Military EU Topical Hemostatic Market US Topical Hemostatic Market MedMarket Diligence, LLC and other interna
Slide 10: How Much Funding and Dynasil Position
How Much Funding and Dynasil Position 18 - Month Funding Plan CBI $1.5 M Loan DYSL $1.2 M Investment Revised Cap Table
Slide 11: Funding to First Value Inflection Point
Funding to 1 st Value Inflection Point • Xcede funding for next 18 months has been provided by: – P. Sulick $450,000 Bridge Investment – DYSL $1.2 million for G&A – Cook Biotech Inc. (CBI) commitment of $1.5 million to Xcede • Biocomp , toxicology & survivability studies • First - in - human clinica
Slide 12: CBI Funding of Xcede FIH
CBI Funding of Xcede FIH: Commitment of $1.5M CBI funding (non dilutive): • CBI to perform clinical work through first - in - human (FIH) trials for up to $1.5 million • Structured as a secured promissory note, 2% interest with an outside maturity date of December 31, 2025 – Loan agreement ($1.5 mil
Slide 13: DYSL Funding of Xcede
DYSL Funding of Xcede Key Terms: • Convertible Series B Preferred Stock • $1.2M funded in 6 tranches across 18 months – Funding to match Xcede projected expenses • Liquidation preference over Convertible Series A Preferred Stock • Conversion on a one for one basis into shares of common stock, subjec
Slide 14: Revised Cap Table
Revised Cap Table* 14 Shares Percentage Dynasil 5,983,000 54% Outside Investors 2,839,000 26% Mayo Foundation 756,000 7% Xcede Management (Options) 1,424,000 13% Total 11,002,000 100% * Fully diluted, as if converted
Slide 15: When? Timeline to Launch
When? Timeline to Launch
Slide 16: Estimated Timeline to Approvals and Launch
Estimated Timeline to Approvals and Launch 16 Q4 2016 2017 2018 2019 2020 2021 Biocomp FIH Clinical CE Mark Filing CE Mark EU Launch US Pivotal Study PMA Filing PMA Approval US Launch Value inflection points
Slide 17: Questions?
y - Questions?
Dynasil Corp of America — Corporate Update (November 2016) on 6ix